Angiodynamics, Inc. · NASDAQ:ANGO

Angiodynamics — Q4 FY2020 Earnings Presentation

9 slides from Angiodynamics's earnings presentation, Jul 16, 2020

  1. Slide 1: AngioDynamics Fourth Quarter 2020 Earnings Presentation

    AngioDynamics Fourth Quarter 2020 Earnings PresentationJuly 16, 2020

  2. Slide 2: Notice Regarding Forward-Looking Statements

    Notice Regarding Forward-Looking StatementsThis presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, business strateg

  3. Slide 3: Fourth Quarter and FY2020 Highlights

    Fourth Quarter and FY2020 Highlights Corporate Developments Procedural volumes troughed in April and began to rebound in early-to-mid May with steady improvement through May and June.Carefully monitored balance sheet and managed expenses, remaining cash flow positive despite lower procedural volumes

  4. Slide 4: Fourth Quarter and YTD FY2020 Results (unaudited)

    Fourth Quarter and YTD FY2020 Results (unaudited) $ in thousands (except per share data) FY2020Q4 FY2019Q4 Change FY2020YTD FY2019YTD Change Revenue Vascular Interventions and Therapies Vascular Access Oncology United States International $58,33222,09023,71412,52844,59913,733 $71,18231,03024,86915,2

  5. Slide 5: GAAP to Non-GAAP Reconciliation

    GAAP to Non-GAAP Reconciliation

  6. Slide 6: Reconciliation of GAAP to Non-GAAP and EPS Before Goodwill Impairment

    Reconciliation of GAAP to Non-GAAP Net Income (Loss) and EPS Before Goodwill Impairment* Amounts in thousands

  7. Slide 7: Reconciliation of GAAP to Non-GAAP and EPS

    Reconciliation of GAAP to Non-GAAP Net Income (Loss) and EPS Amounts in thousands Write-off of raw materials and existing dosimetry inventory associated with OARtrac that was purchased pursuant to the Company’s acquisition of RadiaDyne. These inventory items were deemed unmarketable absent subsequen

  8. Slide 8: Reconciliation to Adjusted EBITDA

    Reconciliation of Net Income (Loss) to Adjusted EBITDA Amounts in thousands

  9. Slide 9: Growth through Focus Execution Accountability

    Growth through Focus Execution Accountability

AngioDynamics — Q4 FY2020 Earnings Presentation on 6ix